ImmunoGen, Inc. announced the appointment of Stuart A. Arbuckle to its Board of Directors. Mr. Arbuckle is replacing Howard Pien, who is stepping down from ImmunoGen's Board after eight years of service. Mr. Arbuckle has more than 30 years of experience in building biopharmaceutical commercial organizations and has served as Vertex's Executive Vice President and Chief Commercial Officer since 2012, leading the successful global launches of Kalydeco and Orkambi. Prior to joining Vertex, Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc., most recently serving as Vice President and Regional General Manager overseeing the expansion of the company's presence in Japan, Asia, the Middle East, and Africa. As Vice President and General Manager of Amgen's Oncology Business Unit, he was responsible for sales and marketing efforts for Aranesp, Neulasta and NEUPOGEN, and led the successful launches of XGEVA and Nplate. Prior to Amgen, Mr. Arbuckle held commercial roles of increasing responsibility at Celltech Pharmaceuticals and GlaxoSmithKline.